Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P2: Alpelisib in PROS
NCT04589650Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Countries
- 12
01
Overview
A Phase 2 trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS), sponsored by Novartis. Started Apr 2021; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NCT04589650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589650.